Imperial College London
Alternate

DrMatthewWilliams

Faculty of Medicine, Department of Surgery & Cancer

Honorary Senior Research Fellow
 
 
 
//

Contact

 

+44 (0)20 3311 0733matthew.williams Website CV

 
 
//

Location

 

Charing Cross HospitalCharing Cross Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Plaha:2022:10.1136/bmjopen-2022-064823,
author = {Plaha, P and Camp, S and Cook, J and McCulloch, P and Voets, N and Ma, R and Taphoorn, MJB and Dirven, L and Grech-Sollars, M and Watts, C and Bulbeck, H and Jenkinson, MD and Williams, M and Lim, A and Dixon, L and Price, SJ and Ashkan, K and Apostolopoulos, V and Barber, VS and Taylor, A and FUTURE-GB, collaborators and Nandi, D},
doi = {10.1136/bmjopen-2022-064823},
journal = {BMJ Open},
pages = {1--10},
title = {FUTURE-GB: functional and ultrasound-guided resection of glioblastoma - a two-stage randomised control trial.},
url = {http://dx.doi.org/10.1136/bmjopen-2022-064823},
volume = {12},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - INTRODUCTION: Surgery remains the mainstay for treatment of primary glioblastoma, followed by radiotherapy and chemotherapy. Current standard of care during surgery involves the intraoperative use of image-guidance and 5-aminolevulinic acid (5-ALA). There are multiple other surgical adjuncts available to the neuro-oncology surgeon. However, access to, and usage of these varies widely in UK practice, with limited evidence of their use. The aim of this trial is to investigate whether the addition of diffusion tensor imaging (DTI) and intraoperative ultrasound (iUS) to the standard of care surgery (intraoperative neuronavigation and 5-ALA) impacts on deterioration free survival (DFS). METHODS AND ANALYSIS: This is a two-stage, randomised control trial (RCT) consisting of an initial non-randomised cohort study based on the principles of the IDEAL (Idea, Development, Exploration, Assessment and Long-term follow-up) stage-IIb format, followed by a statistically powered randomised trial comparing the addition of DTI and iUS to the standard of care surgery. A total of 357 patients will be recruited for the RCT. The primary outcome is DFS, defined as the time to either 10-point deterioration in health-related quality of life scores from baseline, without subsequent reversal, progressive disease or death. ETHICS AND DISSEMINATION: The trial was registered in the Integrated Research Application System (Ref: 264482) and approved by a UK research and ethics committee (Ref: 20/LO/0840). Results will be published in a peer-reviewed journal. Further dissemination to participants, patient groups and the wider medical community will use a range of approaches to maximise impact. TRIAL REGISTRATION NUMBER: ISRCTN38834571.
AU  - Plaha,P
AU  - Camp,S
AU  - Cook,J
AU  - McCulloch,P
AU  - Voets,N
AU  - Ma,R
AU  - Taphoorn,MJB
AU  - Dirven,L
AU  - Grech-Sollars,M
AU  - Watts,C
AU  - Bulbeck,H
AU  - Jenkinson,MD
AU  - Williams,M
AU  - Lim,A
AU  - Dixon,L
AU  - Price,SJ
AU  - Ashkan,K
AU  - Apostolopoulos,V
AU  - Barber,VS
AU  - Taylor,A
AU  - FUTURE-GB,collaborators
AU  - Nandi,D
DO  - 10.1136/bmjopen-2022-064823
EP  - 10
PY  - 2022///
SN  - 2044-6055
SP  - 1
TI  - FUTURE-GB: functional and ultrasound-guided resection of glioblastoma - a two-stage randomised control trial.
T2  - BMJ Open
UR  - http://dx.doi.org/10.1136/bmjopen-2022-064823
UR  - https://www.ncbi.nlm.nih.gov/pubmed/36379652
UR  - https://bmjopen.bmj.com/content/12/11/e064823
UR  - http://hdl.handle.net/10044/1/102975
VL  - 12
ER  -
Download